These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 14967552)

  • 1. Overvalued ideation as a predictor of fluvoxamine response in patients with obsessive-compulsive disorder.
    Neziroglu F; Pinto A; Yaryura-Tobias JA; McKay D
    Psychiatry Res; 2004 Jan; 125(1):53-60. PubMed ID: 14967552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive validity of the overvalued ideas scale: outcome in obsessive-compulsive and body dysmorphic disorders.
    Neziroglu F; Stevens KP; McKay D; Yaryura-Tobias JA
    Behav Res Ther; 2001 Jun; 39(6):745-56. PubMed ID: 11400717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder.
    Landeros-Weisenberger A; Bloch MH; Kelmendi B; Wegner R; Nudel J; Dombrowski P; Pittenger C; Krystal JH; Goodman WK; Leckman JF; Coric V
    J Affect Disord; 2010 Feb; 121(1-2):175-9. PubMed ID: 19577308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Motivation to change as a predictor of treatment response in obsessive compulsive disorder.
    Pinto A; Pinto AM; Neziroglu F; Yaryura-Tobias JA
    Ann Clin Psychiatry; 2007; 19(2):83-7. PubMed ID: 17612847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of selective serotonin reuptake inhibitors on thought-action fusion, metacognitions, and thought suppression in obsessive-compulsive disorder.
    Besiroglu L; Çetinkaya N; Selvi Y; Atli A
    Compr Psychiatry; 2011; 52(5):556-61. PubMed ID: 21109243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized controlled trial of Japanese patients with obsessive-compulsive disorder--effectiveness of behavior therapy and fluvoxamine.
    Nakatani E; Nakagawa A; Nakao T; Yoshizato C; Nabeyama M; Kudo A; Isomura K; Kato N; Yoshioka K; Kawamoto M
    Psychother Psychosom; 2005; 74(5):269-76. PubMed ID: 16088264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Overvalued Ideas Scale: development, reliability and validity in obsessive-compulsive disorder.
    Neziroglu F; McKay D; Yaryura-Tobias JA; Stevens KP; Todaro J
    Behav Res Ther; 1999 Sep; 37(9):881-902. PubMed ID: 10458051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy.
    Alonso P; Menchon JM; Pifarre J; Mataix-Cols D; Torres L; Salgado P; Vallejo J
    J Clin Psychiatry; 2001 Jul; 62(7):535-40. PubMed ID: 11488364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression.
    Apter A; Ratzoni G; King RA; Weizman A; Iancu I; Binder M; Riddle MA
    J Am Acad Child Adolesc Psychiatry; 1994; 33(3):342-8. PubMed ID: 8169178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma fluvoxamine levels and OCD symptoms/response in adult patients.
    Marazziti D; Baroni S; Giannaccini G; Piccinni A; Picchetti M; Massimetti G; Schiavi E; Palego L; Catena-Dell'Osso M
    Hum Psychopharmacol; 2012 Jul; 27(4):397-402. PubMed ID: 22806821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of trauma and post-traumatic stress disorder on the treatment response of patients with obsessive-compulsive disorder.
    Shavitt RG; Valério C; Fossaluza V; da Silva EM; Cordeiro Q; Diniz JB; Belotto-Silva C; Cordioli AV; Mari J; Miguel EC
    Eur Arch Psychiatry Clin Neurosci; 2010 Mar; 260(2):91-9. PubMed ID: 20077119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obsessive-compulsive disorder: an open-label pilot trial of escitalopram.
    Galvão-de Almeida A; Quarantini LC; Góis CR; Santos-Jesus R; Miranda-Scippa AM; de Oliveira IR; da Silva Prado H; Leckman JF; Rosário MC
    CNS Spectr; 2007 Jul; 12(7):519-24. PubMed ID: 17603402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.
    Hollander E; Koran LM; Goodman WK; Greist JH; Ninan PT; Yang H; Li D; Barbato LM
    J Clin Psychiatry; 2003 Jun; 64(6):640-7. PubMed ID: 12823077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic and pharmacogenetic study of glutamate transporter (SLC1A1) in Iranian patients with obsessive-compulsive disorder.
    Abdolhosseinzadeh S; Sina M; Ahmadiani A; Asadi S; Shams J
    J Clin Pharm Ther; 2019 Feb; 44(1):39-48. PubMed ID: 30315580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive therapy and exposure in vivo alone and in combination with fluvoxamine in obsessive-compulsive disorder: a 5-year follow-up.
    van Oppen P; van Balkom AJ; de Haan E; van Dyck R
    J Clin Psychiatry; 2005 Nov; 66(11):1415-22. PubMed ID: 16420079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: A randomized double-blind, placebo-controlled study.
    Zheng H; Jia F; Han H; Wang S; Guo G; Quan D; Li G; Huang H
    Eur Neuropsychopharmacol; 2019 Mar; 29(3):397-404. PubMed ID: 30595354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preschool children with obsessive-compulsive disorder and fluoxetine treatment.
    Ercan ES; Kandulu R; Akyol Ardic U
    Eur Child Adolesc Psychiatry; 2012 Mar; 21(3):169-72. PubMed ID: 22271063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of treatment response to fluvoxamine in obsessive-compulsive disorder: an fMRI study.
    Sanematsu H; Nakao T; Yoshiura T; Nabeyama M; Togao O; Tomita M; Masuda Y; Nakatani E; Nakagawa A; Kanba S
    J Psychiatr Res; 2010 Mar; 44(4):193-200. PubMed ID: 19758599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing the Effects of a Herbal Drug based on
    Noras MR; Soltanifar A; Salari R; Jarahi L; Abrishami MH
    Curr Drug Discov Technol; 2022; 19(5):e240622206368. PubMed ID: 35748547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.